146 related articles for article (PubMed ID: 31977312)
1. Dapagliflozin restores insulin and growth hormone secretion in obese mice.
Huang Z; Huang L; Wang C; Zhu S; Qi X; Chen Y; Zhang Y; Cowley MA; Veldhuis JD; Chen C
J Endocrinol; 2020 Apr; 245(1):1-12. PubMed ID: 31977312
[TBL] [Abstract][Full Text] [Related]
2. Suppression of hyperinsulinemia restores growth hormone secretion and metabolism in obese mice.
Huang Z; Lu X; Huang L; Chen Y; Zhang C; Veldhuis JD; Chen C
J Endocrinol; 2021 Jul; 250(3):105-116. PubMed ID: 34156345
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of endogenous pulsatile growth hormone secretion by activation of growth hormone secretagogue receptor reduces the fat accumulation and improves the insulin sensitivity in obese mice.
Huang Z; Lu X; Huang L; Zhang C; Veldhuis JD; Cowley MA; Chen C
FASEB J; 2021 Jan; 35(1):e21269. PubMed ID: 33368660
[TBL] [Abstract][Full Text] [Related]
4. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
Millar PJ; Pathak V; Moffett RC; Pathak NM; Bjourson AJ; O'Kane MJ; Flatt PR; Gault VA
Mol Cell Endocrinol; 2016 Jan; 420():37-45. PubMed ID: 26607806
[TBL] [Abstract][Full Text] [Related]
5. Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak L; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2021-2033. PubMed ID: 29572114
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin partially restores reproductive function in MC4R KO obese female mice.
Cui L; Tan C; Huang L; Wang W; Huang Z; Geng F; Wu M; Chen X; Cowley M; Roelfsema F; Chen C
J Endocrinol; 2022 Jun; 254(2):65-76. PubMed ID: 35612570
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
[TBL] [Abstract][Full Text] [Related]
8. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
[TBL] [Abstract][Full Text] [Related]
9. Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity.
Joannides CN; Mangiafico SP; Waters MF; Lamont BJ; Andrikopoulos S
Diabetes Obes Metab; 2017 Aug; 19(8):1135-1146. PubMed ID: 28244693
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.
Wei R; Cui X; Feng J; Gu L; Lang S; Wei T; Yang J; Liu J; Le Y; Wang H; Yang K; Hong T
Metabolism; 2020 Oct; 111():154324. PubMed ID: 32712220
[TBL] [Abstract][Full Text] [Related]
11. Time-Restricted Feeding Restored Insulin-Growth Hormone Balance and Improved Substrate and Energy Metabolism in MC4RKO Obese Mice.
Wang W; Huang Z; Huang L; Gao L; Cui L; Cowley M; Guo L; Chen C
Neuroendocrinology; 2022; 112(2):174-185. PubMed ID: 33735897
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
Tanday N; Irwin N; Flatt PR; Moffett RC
Biochem Pharmacol; 2020 Jul; 177():114009. PubMed ID: 32360307
[TBL] [Abstract][Full Text] [Related]
13. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
Xu L; Nagata N; Nagashimada M; Zhuge F; Ni Y; Chen G; Mayoux E; Kaneko S; Ota T
EBioMedicine; 2017 Jun; 20():137-149. PubMed ID: 28579299
[TBL] [Abstract][Full Text] [Related]
15. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
Latva-Rasku A; Honka MJ; Kullberg J; Mononen N; Lehtimäki T; Saltevo J; Kirjavainen AK; Saunavaara V; Iozzo P; Johansson L; Oscarsson J; Hannukainen JC; Nuutila P
Diabetes Care; 2019 May; 42(5):931-937. PubMed ID: 30885955
[TBL] [Abstract][Full Text] [Related]
16. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability.
Díaz-Rodríguez E; Agra RM; Fernández ÁL; Adrio B; García-Caballero T; González-Juanatey JR; Eiras S
Cardiovasc Res; 2018 Feb; 114(2):336-346. PubMed ID: 29016744
[TBL] [Abstract][Full Text] [Related]
17. Treatment with dapagliflozin increases FGF-21 gene expression and reduces triglycerides content in myocardial tissue of genetically obese mice.
Di Vincenzo A; Crescenzi M; Granzotto M; Vecchiato M; Fioretto P; Vettor R; Rossato M
J Endocrinol Invest; 2024 Jul; 47(7):1777-1786. PubMed ID: 38194168
[TBL] [Abstract][Full Text] [Related]
18. Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice.
Han T; Fan Y; Gao J; Fatima M; Zhang Y; Ding Y; Bai L; Wang C
Adipocyte; 2021 Dec; 10(1):446-455. PubMed ID: 34550043
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats.
Swe MT; Thongnak L; Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Lungkaphin A
Clin Sci (Lond); 2019 Dec; 133(23):2415-2430. PubMed ID: 31769484
[TBL] [Abstract][Full Text] [Related]
20. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
Toxicol Appl Pharmacol; 2017 Oct; 333():43-50. PubMed ID: 28807765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
